Oncogenic driver and therapeutic target: Prolactin signalling axis in retroperitoneal sarcoma

Abstract

Background: Retroperitoneal sarcoma (RPS) is a type of malignant tumour arising from mesenchymal tissues within the retroperitoneal space. RPSs tend to develop covertly and are often undiscovered when they have already grown significantly and invaded surrounding tissues and organs. These malignancies demonstrate high recurrence rates, present surgical challenges and exhibit limited responsiveness to radiotherapy and chemotherapy. Serum-derived molecules are known to play critical roles in tumourigenesis and tumour progression. However, the serum molecular profile of RPS patients remains unclear.

Methods: We performed multi-omics analysis of serum samples from patients with retroperitoneal dedifferentiated liposarcoma. Prolactin concentrations were quantified using Enzyme-Linked Immunosorbent Assay (ELISA). RNA-seq facilitated the identification of candidate signalling pathways, while gene expression was validated through quantitative polymerase chain reaction, immunohistochemistry and western blot analyses. Molecular mechanisms underlying transcriptional regulation were investigated through Chromatin Immunoprecipitation-qPCR (ChIP-qPCR) and dual-luciferase reporter gene assays.

Results: Integrative multi-omics profiling identified significant perturbations in galactose metabolism coupled with marked elevation of prolactin (PRL) levels in Retroperitoneal Liposarcoma (RLPS) patients. Further screening of serum prolactin levels in 100 patients with retroperitoneal tumours revealed that 90% of the cases exhibited hyperprolactinaemia in our research cohort, encompassing both malignant sarcomas and benign tumours. Studies at the clinical sample, cellular and animal levels have found that abnormally elevated prolactin in the serum can originate from sarcoma tissues. Mechanistic investigations identified SRY-box transcription factor 4 (SOX4) as a previously unrecognised transcriptional regulator of PRL. Functionally, PRL not only enhanced liposarcoma cell and fibrosarcoma cell proliferation but also conferred resistance to MDM2 inhibitors. Signalling pathway analysis revealed that PRL activates the Janus Kinase–Signal Transducer and Activator of Transcription Pathway (JAK–STAT) signalling pathway and up-regulates c-MYC expression.

Conclusions: This study indicates that PRL can serve as an oncogenic driver and therapeutic target. The identification of SOX4–PRL–c-MYC signalling axis provides actionable insights for developing novel therapeutic strategies against this malignancy.

Key points:

Keywords

c-MYC / hyperprolactinaemia / lactose / prolactin / retroperitoneal sarcoma / SOX4

References

[1] Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: an update on the current state of histiotype-specific management in an era of personalized medicine. CA Cancer J Clin. 2020; 70: 200-229.

[2] Kallen ME, Hornick JL. The 2020 WHO classification: what's new in soft tissue tumor pathology?. Am J Surg Pathol. 2021; 45: e1-e23.

[3] Gatta G, Capocaccia R, Botta L, et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol. 2017; 18: 1022-1039.

[4] Lahat G, Tuvin D, Wei C, et al. New perspectives for staging and prognosis in soft tissue sarcoma. Ann Surg Oncol. 2008; 15: 2739-2748.

[5] Gronchi A, Miceli R, Allard MA, et al. Personalizing the approach to retroperitoneal soft tissue sarcoma: histology-specific patterns of failure and postrelapse outcome after primary extended resection. Ann Surg Oncol. 2015; 22: 1447-1454.

[6] Yeh YT, Lee KT, Tsai CJ, Chen YJ, Wang SN. Prolactin promotes hepatocellular carcinoma through Janus kinase 2. World J Surg. 2012; 36: 1128-1135.

[7] Schuler LA, O'Leary KA. Prolactin: the third hormone in breast cancer. Front Endocrinol. (Lausanne) 2022; 13:910978.

[8] Clendenen TV, Arslan AA, Lokshin AE, et al. Circulating prolactin levels and risk of epithelial ovarian cancer. Cancer Causes Control. 2013; 24: 741-748.

[9] Halbreich U, Kinon BJ, Gilmore JA, Kahn LS. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology. 2003; 28 Suppl 1: 53-67.

[10] Shen H, He T, Wang S, et al. SOX4 promotes beige adipocyte-mediated adaptive thermogenesis by facilitating PRDM16-PPARgamma complex. Theranostics. 2022; 12: 7699-7716.

[11] Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E. Phase II trial of gemcitabine in advanced sarcomas. Cancer. 2002; 94: 3225-3229.

[12] Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014; 11: 783-784.

[13] Huang P, Deng W, Bao H, et al. SOX4 facilitates PGR protein stability and FOXO1 expression conducive for human endometrial decidualization. eLife. 2022; 11:e72073.

[14] Wang S, He T, Luo Y, et al. SOX4 facilitates brown fat development and maintenance through EBF2-mediated thermogenic gene program in mice. Cell Death Differ. 2024;32: 447-465.

[15] Yoo S, Ko CH, Lowrey PL, et al. A noncanonical E-box enhancer drives mouse Period2 circadian oscillations in vivo. Proc Natl Acad Sci USA. 2005; 102: 2608-2613.

[16] Chen Q, Zhuang S, Hong Y, et al. Demethylase JMJD2D induces PD-L1 expression to promote colorectal cancer immune escape by enhancing IFNGR1-STAT3-IRF1 signaling. Oncogene. 2022; 41: 1421-1433.

[17] Xiao M, Qin D, Li X, et al. Prognosis-oriented molecular subtypes of retroperitoneal liposarcoma. Clin Transl Med. 2024; 14:e70050.

[18] Gerlo S, Verdood P, Hooghe-Peters EL, Kooijman R. Multiple, PKA-dependent and PKA-independent, signals are involved in cAMP-induced PRL expression in the eosinophilic cell line Eol-1. Cell Signal. 2005; 17: 901-909.

[19] Xie F, Niu Y, Chen X, et al. Ursodeoxycholic acid inhibits the uptake of cystine through SLC7A11 and impairs de novo synthesis of glutathione. J Pharm Anal. 2025; 15:101068.

[20] Sciot R. MDM2 amplified sarcomas: a literature review. Diagnostics (Basel). 2021; 11(3): 496.

[21] Traweek RS, Cope BM, Roland CL, Keung EZ, Nassif EF, Erstad DJ. Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma. Front Oncol. 2022; 12:1006959.

[22] Lopez-Mejia JA, Mantilla-Ollarves JC, Rocha-Zavaleta L. Modulation of JAK-STAT signaling by LNK: a forgotten oncogenic pathway in hormone receptor-positive breast cancer. Int J Mol Sci. 2023; 24(19):14777.

[23] Huang L, Liu D, Wang N, et al. Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. Cell Res. 2018; 28: 172-186.

[24] Clevenger CV, Rui H. Breast cancer and prolactin—new mechanisms and models. Endocrinology. 2022; 163(10):bqac122.

[25] Jacobson EM, Hugo ER, Tuttle TR, Papoian R, Ben-Jonathan N. Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor. Trends Endocrinol Metab. 2010; 21: 691-698.

[26] Karayazi AO, Govindrajan N, Lopetegui-Gonzalez I, Shemanko CS. Prolactin: a hormone with diverse functions from mammary gland development to cancer metastasis. Semin Cell Dev Biol. 2021; 114: 159-170.

[27] Bonvalot S, Raut CP, Pollock RE, et al. Technical considerations in surgery for retroperitoneal sarcomas: position paper from E-Surge, a master class in sarcoma surgery, and EORTC-STBSG. Ann Surg Oncol. 2012; 19: 2981-2991.

[28] Fairweather M, Gonzalez RJ, Strauss D, Raut CP. Current principles of surgery for retroperitoneal sarcomas. J Surg Oncol. 2018; 117: 33-41.

[29] Permana MY, Sarwanti S, Fauziah S. Effectivity of bromocriptine administration towards prolactin positive breast cancer receiving anthracycline-based chemotherapy: a literature review. Acta Med Indones. 2023; 55: 465-474.

[30] Auriemma RS, Pirchio R, Pivonello C, Garifalos F, Colao A, Pivonello R. Approach to the patient with prolactinoma. J Clin Endocrinol Metab. 2023; 108: 2400-2423.

[31] Li R, Yang Y, Lan H, et al. A novel mechanism of hPRL-G129R, a prolactin antagonist, inhibits human breast cancer cell proliferation and migration. Endocrinology. 2023; 164(12):bqad15.

[32] Damiano JS, Rendahl KG, Karim C, et al. Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer. Mol Cancer Ther. 2013; 12: 295-305.

[33] Pardanani A, Harrison C, Cortes JE, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 2015; 1: 643-651.

[34] Constantinescu SN, Pecquet C. Degrading JAK2 in ALL by ruxolitinib-based PROTACs. Blood. 2021; 138: 2301-2302.

[35] Shim JC, Shin JG, Kelly DL, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007; 164: 1404-1410.

[36] Bouchard P, Lagoguey M, Brailly S, Schaison G. Gonadotropin-releasing hormone pulsatile administration restores luteinizing hormone pulsatility and normal testosterone levels in males with hyperprolactinemia. J Clin Endocrinol Metab. 1985; 60: 258-262.

[37] Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics–a review. Hum Psychopharmacol. 2010; 25: 281-297.

[38] Bushe CJ, Bradley A, Pendlebury J. A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry?. Ann Clin Biochem. 2010; 47: 292-300.

[39] Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004; 64: 2291-2314.

[40] Ma L, Gao JS, Guan Y, et al. Acetylation modulates prolactin receptor dimerization. Proc Natl Acad Sci USA. 2010; 107: 19314-19319.

[41] Klein AM, de Queiroz RM, Venkatesh D, Prives C. The roles and regulation of MDM2 and MDMX: it is not just about p53. Genes Dev. 2021; 35: 575-601.

[42] Zeng Q, Zeng S, Dai X, et al. MDM2 inhibitors in cancer immunotherapy: current status and perspective. Genes Dis. 2024; 11:101279.

[43] Bill KL, Garnett J, Meaux I, et al. SAR405838: a novel and potent inhibitor of the MDM2:p53 axis for the treatment of dedifferentiated liposarcoma. Clin Cancer Res. 2016; 22: 1150-1160.

[44] Thoenen E, Curl A, Iwakuma T. TP53 in bone and soft tissue sarcomas. Pharmacol Ther. 2019; 202: 149-164.

[45] Menon AA, Deshpande V, Suster D. MDM2 for the practicing pathologist: a primer. J Clin Pathol. 2023; 76: 285-290.

[46] de Queiroz RM, Efe G, Guzman A, et al. Mdm2 requires Sprouty4 to regulate focal adhesion formation and metastasis independent of p53. Nat Commun. 2024; 15: 7132.

[47] Shu J, Jiang J, Wang X, Yang X, Zhao G, Cai T. MDM2 provides TOP2 poison resistance by promoting proteolysis of TOP2betacc in a p53-independent manner. Cell Death Dis. 2024; 15: 83.

[48] Cisse MY, Pyrdziak S, Firmin N, et al. Targeting MDM2-dependent serine metabolism as a therapeutic strategy for liposarcoma. Sci Transl Med. 2020; 12(547):eaay2163.

[49] Liu J, Mai Y, Wang Y, et al. RAB3D/MDM2/beta-catenin/c-MYC axis exacerbates the malignant behaviors of acute myeloid leukemia cells in vitro and in vivo. Cancer Gene Ther. 2023; 30: 335-344.

[50] Faruq O, Zhao D, Shrestha M, Vecchione A, Zacksenhaus E, Chang H. Targeting an MDM2/MYC axis to overcome drug resistance in multiple myeloma. Cancers (Basel). 2022; 14(6): 1592.

[51] Sui X, Shin S, Zhang R, et al. Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells. Oncogene. 2009; 28: 709-720.

[52] Xu J, Zhang Y, Berry PA, et al. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex. Mol Endocrinol. 2011; 25: 597-610.

[53] Carvalho-Freitas MI, Rodrigues-Costa EC, Nasello AG, Palermo-Neto J, Felicio LF. In vitro macrophage activity: biphasic effect of prolactin and indirect evidence of dopaminergic modulation. NeuroImmunoModulation. 2008; 15: 131-139.

[54] Huang C, Snider F, Cross JC. Prolactin receptor is required for normal glucose homeostasis and modulation of beta-cell mass during pregnancy. Endocrinology. 2009; 150: 1618-1626.

[55] Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017; 18: 1493-1501.

[56] D'Angelo SP, Mahoney MR, Van Tine BA, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018; 19: 416-426.

[57] Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001; 22: 724-763.

[58] Watanabe K, Kessler CA, Bachurski CJ, et al. Identification of a decidua-specific enhancer on the human prolactin gene with two critical activator protein 1 (AP-1) binding sites. Mol Endocrinol. 2001; 15: 638-653.

[59] Gaasenbeek M, Gellersen B, DiMattia GE. DNase I hypersensitivity analysis of non-pituitary human prolactin gene expression. Mol Cell Endocrinol. 1999; 152: 147-159.

[60] Christian M, Pohnke Y, Kempf R, Gellersen B, Brosens JJ. Functional association of PR and CCAAT/enhancer-binding protein beta isoforms: promoter-dependent cooperation between PR-B and liver-enriched inhibitory protein, or liver-enriched activatory protein and PR-A in human endometrial stromal cells. Mol Endocrinol. 2002; 16: 141-154.

[61] Yang X, Meyer K, Friedl A. STAT5 and prolactin participate in a positive autocrine feedback loop that promotes angiogenesis. J Biol Chem. 2013; 288: 21184-21196.

[62] Suzuki S, Handa RJ. Estrogen receptor-beta, but not estrogen receptor-alpha, is expressed in prolactin neurons of the female rat paraventricular and supraoptic nuclei: comparison with other neuropeptides. J Comp Neurol. 2005; 484: 28-42.

[63] Langan EA, Ramot Y, Hanning A, et al. Thyrotropin-releasing hormone and oestrogen differentially regulate prolactin and prolactin receptor expression in female human skin and hair follicles in vitro. Br J Dermatol. 2010; 162: 1127-1131.

[64] Liu T, Wang J, Yang H, et al. Enhancer coamplification and hijacking promote oncogene expression in liposarcoma. Cancer Res. 2023; 83: 1517-1530.

[65] McFarland-Mancini M, Hugo E, Loftus J, Ben-Jonathan N. Induction of prolactin expression and release in human preadipocytes by cAMP activating ligands. Biochem Biophys Res Commun. 2006; 344: 9-16.

[66] Henricks WH, Chu YC, Goldblum JR, Weiss SW. Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Pathol. 1997; 21: 271-281.

[67] Gruel N, Quignot C, Lesage LT, et al. Cellular origin and clonal evolution of human dedifferentiated liposarcoma. Nat Commun. 2024; 15: 7941.

RIGHTS & PERMISSIONS

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.